REFERENCES
- Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–1888.
- Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103–1109.
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39.
- van der Noll R, Leijen S, Neuteboom GHG, et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev. 2013;39:664–672.
- Huillard A, Bakalian S, Levy C, et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review. Eur J Cancer. 2014;50:638–648.
- Moorthy RS, Inomata H. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–292.
- Cho H, Pillai P, Nicholson L, et al. Inflammatory papillitis in uveitis: response to treatment and use of optic nerve optical coherence tomography for monitoring. Ocul Immuno Inflamm. 2016;24:194–206.